Tranexamic acid 1197-18-8 CAS NO.1197-18-8

Shanghai SOYOUNG onsite assessment conducted by Bureau Veritas commissioned at June 2018. Assessed Supplier of Shanghai SOYOUNG is a faithful and professional supplier of health raw materials in pharmacy, food, cosmetic and other fields for many years, with own laboratories and GMP standard factories.

1. 12 years specialized in health products field.
2. GMP/ISO certificated factories and stable supply chain.
3. Quality first, strictly control before shipments.
4. Custom synthesis by more than 20 professional chemists.
5. Small order,free sample and one step service available.
6. Rapid delivery, 1-6 business days from China warehouse.
7. Support 7 days refund money in case delay shipment.
8. Assessment conducted by Bureau Veritas at 2018.

【Item name】Tranexamic acid
【Synonyms】 Chloric acid; Tosemin; 4-aminomethyl cyclohexane formic acid; 4-(aminomethyl)cyclohexane-1-carboxylic acid; trans-cyclohexanecarboxylic acid; trans-4-(Aminomethyl)cyclohexanecarboxylic acid;  
【CAS NO.】 1197-18-8; 701-54-2
【Mol. Formula】 C8H15NO2                                         
【Mol. Weight】 157.21
【Assay】 99.0-101.0%
【Appearance】 White or almost white crystalline powder 
【Standard】 Medicine grade (CP/BP/EP/JP/USP)
【Packing】 25kgs/drum (standard packing)
【Storage】 Tight container, protect from light

Tranexamic acid, also known as chloric acid, chemical name 4-aminomethyl cyclohexane formic acid, trade name Tosemin.Tranexamic acid (tranexamicacid) is a synthetic amino acid antifibrinolytic drug, which can competitively inhibit the binding of fibrin lysine to fibrinolytic enzyme, thus inhibit the cleavage of fibrin clot and produce hemostatic effect. Tranexamic acid freely soluble in water and in glacial acetic acid, practically insoluble in acetone and in alcohol.

Quality standard 

Function

Tranexamic acid is used to treat or prevent excessive blood loss during surgery and in various other medical conditions. It is anantifibrinolytic that competitively inhibits the activation of plasminogen to plasmin, by binding to specific sites of both plasminogen and plasmin, a molecule responsible for the degradation of fibrin, a protein that forms the framework of blood clots. Tranexamic acid has roughly eight times theantifibrinolytic activity of an older analogue, ε-aminocaproic acid.

Tranexamic acid exerts its antifibrinolytic effect through the reversible blockade of lysinebinding sites on plasminogen molecules.Tranexamic acid inhibits endometrial plasminogen activator and thus prevents fibrinolysis and the breakdown of blood clots. Tranexamic acid is used as firstline nonhormonal treatment of dysfunctional uterine bleeding,and heavy bleeding associated withuterine fibroids. The histological appearance of the necrosis in women treated by tranexamic acid is no different from the spontaneous incidence of thrombosis.

We warmly welcome customers from at home and abroad to establish cooperation and create a bright future with us together. And leading the way to make health industries heathier, help more people healthy and happy…